Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Sanofi Ink Companion Dx Deal

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today said that it will collaborate with Sanofi US on identifying biomarkers that could become a molecular companion diagnostic test.

The potential test would identify patients most likely to respond to an investigational drug being developed by Sanofi.

HTG Molecular, a privately-held, Tucson, Ariz.-based firm, will use its qNPA technology to measure mRNA and/or miRNA expression in formalin fixed paraffin embedded tumor samples. The technology, according to the firm, enables physicians to verify the presence of certain biomarkers relevant to patient selection and therapy.

Financial and other terms of the alliance were not disclosed.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.